Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 years in Asia
Outcome
To assess the efficacy of the CYD dengue vaccine against symptomatic, virologically confirmed dengue in children
Sponsor
Sanofi Pasteur
Date
-
Subjects
748 subjects